FindTrial
Sign In

Effect of application prophylactic tetanus active and passive immune agents on tetanus antibody titers in vivo: an observational study

Effect of application prophylactic tetanus active and passive immune agents on tetanus antibody titers in vivo: an observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096152
Enrollment
Unknown
Registered
2025-01-20
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tetanus

Interventions

HTIG injection (250 IU) + TTCV inoculation group:None
Group injected with HTIG (250 IU):None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
46 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.No HTIG or F(ab')2/TAT injection has been received within six months; or have not received a TTCV in 10 years Species (including incomplete inoculation); 2. 65 years old> = age>46 years old (born before January 1, 1978).

Exclusion criteria

Exclusion criteria: 1.Combined with major organ dysfunction (including cardiopulmonary disease; Liver disease; Kidney disease; Endocrine system and metabolic disorders, immune system diseases), mental diseases; 2.duration of pregnancy.

Design outcomes

Primary

MeasureTime frame
Tetanus antibody concentration;—

Countries

China

Contacts

Public ContactFan Zhao

Peking University Shenzhen Hospital

761216457@qq.com+86 755 83923333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026